Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › AUROPHARMA

AUROPHARMA

Aurobindo Pharma Limited
Mid-capPharma ↗

What the six lenses say about AUROPHARMA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1587.4
2026-07-10
VWAP · 1Y anchor
₹1243
+27.7% from VWAP
P/E · TTM
26.3×
TTM EPS ₹60.3
52-week range
94%
position low→high
RSI(14)
61
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How AUROPHARMA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.5
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD995›

The actual numbers

Price vs VWAP (1y)+27.7%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+19.8%
Price vs 50-EMA+7.1%
RSI(14)61
RS vs Nifty 500 · 3M+14.4%
RS vs sector · 3M+1.9%
52-week range94%
Volume vs 30d avg0.79×
Volume vs 60d avg0.81×
ATR(14) · volatility44.0
Bollinger width · vol contraction0.167
FundamentalD343›

The actual numbers

Return on equity (ROE)10.1%
Return on capital (ROCE)12.8%
Operating margin16.3%
Net margin10.4%
Revenue growth · YoY+6.1%
EPS growth · YoY+0.9%
Debt / equity0.21×

Full 8-quarter history in the financials table below.

ValuationD627›

The actual numbers

P/E (TTM)26.3×
TTM EPS₹60.3
52-week range94%
CatalystD1071›

The actual numbers

Earnings & momentum59
Capital actions77
Governance183

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding51.8%
Delivery · 30d avg47.0%
Up/down-day asymmetry-2.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D6 ) ÷ 2 = 7.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
91
Conviction score 91/100 · avg-decile strength 7.5/10
Conviction score91/100›
TechnicalD9›
FundamentalD3›
ValuationD6›
CatalystD10›
FlowD6›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+1.6pp
+2.6pp
+6.0pp
+18.0pp
+39.1pp
+46.0pp
Nifty 500
Broad-market baseline
+1.2pp
+2.5pp
+5.4pp
+14.4pp
+34.1pp
+42.2pp
Sector
Own-sector index
—
—
+3.0pp
+1.9pp
+19.7pp
+24.3pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

AUROPHARMA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1587.40+30.00

Relative strength

RS vs baseline · rebased to 100

AUROPHARMA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
118.19+1.36

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)7,5677,7967,9798,3827,8688,2868,6468,853
↳ change QoQ—+3.0%+2.3%+5.1%-6.1%+5.3%+4.3%+2.4%
EBITDA (₹cr)1,8411,7021,7351,7601,6031,6781,7731,750
EBITDA margin24.3%21.8%21.8%21.0%20.4%20.3%20.5%19.8%
PAT (₹cr)918817846903824848910921
↳ change QoQ—-11.0%+3.5%+6.8%-8.7%+2.9%+7.3%+1.2%
Net margin12.1%10.5%10.6%10.8%10.5%10.2%10.5%10.4%
EPS (₹)15.6914.0014.5615.5614.2014.6115.6715.86
D/E————————
YoY growth · Mar '26Revenue +5.6% YoYPAT +2.0% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 19 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 Jun '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 12 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 9 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 3 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 3 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    HIGHcapital
    Acquisition
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds AUROPHARMA

Mutual funds holding AUROPHARMA (10)

FundWeightAUM ₹crGrade
HDFC Mid Cap Gr1.96%97,350
SBI Large & Midcap Reg Gr2.07%40,850
SBI ELSS Tax Saver Reg Gr0.74%31,839
HDFC Large and Mid Cap Gr1.08%28,515
SBI Midcap Reg Gr1.99%24,127
SBI Flexicap Reg Gr2.79%22,685
Bandhan Large & Mid Cap Gr0.96%17,461
Quant ELSS Tax Save rGr7.26%13,070
UTI Mid Cap Reg Gr2.05%12,122
Nippon India Pharma Gr1.75%9,044

ETFs holding AUROPHARMA (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF4.72%
ICICI Pru Nifty Healthcare ETF4.02%
Aditya BSL Nifty Healthcare ETF3.84%
DSP Nifty Healthcare ETF3.84%
Axis NIFTY Healthcare ETF3.84%
ICICI Pru BSE Midcap Select ETF3.19%
Mirae Asset Nifty 500 Healthcare ETF3.16%
Motilal Oswal BSE Healthcare ETF2.71%
Kotak Nifty Midcap 50 ETF1.95%
Motilal Oswal Nifty Midcap 100 ETF1.20%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma